US$ 29.45
glp 1 crohn's Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential GLP-1 medications lower heart risks
Description
"Patients may not realize the risks associated with losing lean mass
What is the difference between Ozempic and Mounjaro for muscle loss

On one hand, GLP-1 receptor agonists delivered strong A1C reduction, meaningful weight loss, and cardiovascular benefit
We delineated neuronal and glial mechanisms of insulin resistance and glucagon-like 1 peptide (GLP-1) receptor agonism in human iPSC models of synucleinopathy, and corroborated our findings in patient samples from a Phase 2 trial of a GLP-1R agonist in Parkinsons (NCT01971242)
